Throughout the Covid years, there was a lot of discussion about Ivermectin and its successful role in fighting viruses. Thanks to new research, there are new studies that confirm its unique ability to also cut to the heart of cancer development.
I remember all too well the scary days when I was a young man dealing with Stage 4 Melanoma. When conventional medicine failed me, I was determined not to leave one stone unturned in my search for other ways of healing. That decision led me on a very unexpected journey! And here I am more than 38 years later, reveling in the fact that I am still around to enjoy my grandchildren and to tell my story in the hope of inspiring others.
One of the more surprising things about cancer development was something I learned from a remarkable personal consultation I had with Dr. Hermann Bueno, a world-renowned parasitologist. He told me that he had never seen a case of cancer that didn’t involve parasites. I wouldn’t have had a clue as to consult a parasitologist if it hadn’t been for Ann Louise Gittleman, who said at our first meeting when I attended one of her lectures, “You have that parasitic look.” In all fairness, I asked… and she answered honestly. And I’m so glad she did.
Long story short, she was right. Dr. Bueno’s insights were life-changing for me.
Fast forward and there are some exciting new studies that focus on anti-parasitic therapies such as Ivermectin as they relate to cancer development. And I want to bring them to your attention.
But first, let’s answer the question, “What is Ivermectin and where did it come from?”
The Origin of Ivermectin
Who would have thought that this powerful substance originated from a single microbe from Japanese soil? And yet it did. Ivermectin quickly became a hit with its extraordinary potential for treating parasitic infections in livestock and later humans in the late 1970s.
In an article published in the Journal of Antibiotics, Ivermectin is noted to be an “enigmatic multifaceted ‘wonder’ drug that continues to surprise and exceed expectations. It [ivermectin] continues to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary.”
The Shift to Cancer Research
Ivermectin first made headlines as a possible cancer treatment after preliminary studies demonstrated its potential to target cancer cells. In other words, researchers observed its ability to inhibit cancer cell growth and proliferation while simultaneously inducing apoptosis (programmed cell death).
Key Findings from New 2024 Studies
2024 has been a groundbreaking year for research into Ivermectin. Here are just a few.
- (2024 Kaur et al) – Ivermectin: A multifaceted drug with a potential beyond anti-parasitic therapy. According to this new research, Ivermectin stops cancer cell growth by blocking pathways regulating inflammation – providing further proof that its effectiveness extends far beyond mere parasite therapy and into cancer growth reduction as well as viral infections such as COVID-19.
- (2024 Fan et al) – Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage. According to this new study, Ivermectin could become an invaluable therapy against bladder cancer by inducing oxidative stress and DNA damage that leads to cell apoptosis (cell death).
- (2024 Man-Yuan Li et al) – Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. In this study, researchers demonstrated Ivermectin’s potential in the treatment of lung adenocarcinoma, the most common subtype of lung cancer.
- (2024 Xing Hu et al) – Ivermectin as a potential therapeutic strategy for glioma. Researchers identified multiple mechanisms by which Ivermectin works against tumor cells, including inhibiting certain survival proteins essential for their survival, triggering apoptosis and altering critical signaling pathways related to tumor growth.
- (2024 Yang Song et al) – Gene signatures to therapeutics: Assessing the potential of Ivermectin against t(4;14) multiple myeloma. The t(4;14) subtype is “particularly aggressive and resistant to existing treatments.” In this study, however, researchers demonstrated that Ivermectin significantly slows down Multiple Myeloma (MM) cell growth and is a promising re-purposed drug for treating this form of cancer.
Clinical Trials and Patient Outcomes
The early results are promising and validate what I learned years ago about the parasite connection to cancer. With continued research and clinical trials, perhaps Ivermectin or other anti-parasite medications may soon become an integral part of the oncologist’s toolkit, providing a new ray of hope for those battling this formidable disease.
Related:
Covid and Cancer: The Surprising Connection of the Repurposed Drug Ivermectin in Treating Both
10 Warning Signs of Parasitic Infections
* * * * *
Eat Healthy, Wherever You Are!
Visit the Templeton List